Novavax, Inc.
NVAX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $2 | $0 |
| % Growth | 22.6% | -65.2% | 709.3% | – |
| Cost of Goods Sold | $0 | $0 | $1 | $0 |
| Gross Profit | $0 | $0 | $1 | $0 |
| % Margin | 70.3% | 38.2% | 43.5% | 100% |
| R&D Expenses | $0 | $1 | $1 | $3 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$0 | -$1 |
| Operating Expenses | $1 | $1 | $1 | $2 |
| Operating Income | -$0 | -$1 | -$1 | -$2 |
| % Margin | -36.5% | -101.8% | -40.3% | -853.6% |
| Other Income/Exp. Net | $0 | $0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$1 | -$1 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$1 | -$1 | -$2 |
| % Margin | -27.5% | -98% | -41.1% | -882.5% |
| EPS | -1.23 | -5.41 | -8.42 | -23.44 |
| % Growth | 77.3% | 35.7% | 64.1% | – |
| EPS Diluted | -1.23 | -5.41 | -8.42 | -23.44 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$1 | -$2 |
| % Margin | -15.8% | -87.6% | -37.8% | -850.7% |